释放了Arctium lappa L的抗糖尿病潜力. 根:过程优化,植物化学分析和分子对接,对关键生物活性化合物的洞察力
1Centre for Food Technology, Anna University, Chennai, Tamil Nadu, India.
Preparative biochemistry & biotechnology
|October 29, 2025
概括
使用超声波辅助提取优化的根提取物显示出对治疗2型糖尿病 (T2DM) 的潜力. 提取物有效地抑制了诸如α-amylase和α-glucosidase之类的关键酶,这些酶对血糖控制至关重要.
科学领域:
- 药物鉴定和植物化学学
- 自然产品化学 自然产品化学
- 生物化学和分子生物学
背景情况:
- 2型糖尿病 (T2DM) 的特点是血糖水平高.
- 管理策略包括抑制碳水化合物解酶,如α-氨酶,α-葡萄糖酶和二基酶-4 (DPP-4).
研究的目的:
- 为了优化Arctium lappa L (草根) 的超声波辅助提取 (UAE).
- 为了最大限度地提高总含量 (TPC),总黄含量 (TFC) 和提取产量.
- 评估根提取物在通过酶抑制来控制T2DM中的潜力.
主要方法:
- 超声辅助提取 (UAE) 使用不同的料与溶剂比率,乙醇度,温度和时间.
- 气色谱-质谱 (GC-MS) 用于识别生物活性化合物.
- 分子对接模拟和体外酶抑制试验 (α-氨酶,α-葡萄糖酶).
主要成果:
- 在最佳的阿联条件下,获得高TPC (18.5 mg GAE/g),TFC (7.3 mg QE/g) 和提取收益率 (22.73%).
- GC-MS确定了160种化合物,主要成分包括脂肪酸和pyranone衍生物.
- 接和体外试验证实了根提取物对α-氨酶和α-葡萄糖酶的显著抑制.
结论:
- 优化阿联有效地从罗根中提取生物活性化合物.
- 根提取物显示出抑制碳水化合物解酶的显著潜力.
- 这些发现支持在T2DM管理的功能性食品中使用根提取物.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575


